These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 32430701)

  • 1. Team-Based Approach to Management of Hypertension Associated with Angiogenesis Inhibitors.
    Patel S; Dushenkov A; Jungsuwadee P; Krishnaswami A; Barac A
    J Cardiovasc Transl Res; 2020 Jun; 13(3):463-477. PubMed ID: 32430701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Antihypertensive Drugs in Neoplastic Patients.
    Rizzoni D; De Ciuceis C; Porteri E; Agabiti-Rosei C; Agabiti-Rosei E
    High Blood Press Cardiovasc Prev; 2017 Jun; 24(2):127-132. PubMed ID: 28361339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular Cardio-Oncology: Vascular Endothelial Growth Factor inhibitors and hypertension.
    Versmissen J; Mirabito Colafella KM; Koolen SLW; Danser AHJ
    Cardiovasc Res; 2019 Apr; 115(5):904-914. PubMed ID: 30726882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of hypertension in angiogenesis inhibitor-treated patients.
    Izzedine H; Ederhy S; Goldwasser F; Soria JC; Milano G; Cohen A; Khayat D; Spano JP
    Ann Oncol; 2009 May; 20(5):807-15. PubMed ID: 19150949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uncontrolled Hypertension and Oncology: Clinical Tips.
    Kalaitzidis RG; Elisaf MS
    Curr Vasc Pharmacol; 2017; 16(1):23-29. PubMed ID: 28413967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors.
    Kruzliak P; Novák J; Novák M
    Am J Hypertens; 2014 Jan; 27(1):3-13. PubMed ID: 24168915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy agents and hypertension: a focus on angiogenesis blockade.
    Jain M; Townsend RR
    Curr Hypertens Rep; 2007 Aug; 9(4):320-8. PubMed ID: 17686384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiogenesis and hypertension: the dual role of anti-hypertensive and anti-angiogenic therapies.
    Ferroni P; Della-Morte D; Palmirotta R; Rundek T; Guadagni F; Roselli M
    Curr Vasc Pharmacol; 2012 Jul; 10(4):479-93. PubMed ID: 22272903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.
    Maitland ML; Bakris GL; Black HR; Chen HX; Durand JB; Elliott WJ; Ivy SP; Leier CV; Lindenfeld J; Liu G; Remick SC; Steingart R; Tang WH;
    J Natl Cancer Inst; 2010 May; 102(9):596-604. PubMed ID: 20351338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors.
    Dobbin SJH; Cameron AC; Petrie MC; Jones RJ; Touyz RM; Lang NN
    Heart; 2018 Dec; 104(24):1995-2002. PubMed ID: 30228246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway.
    Hamnvik OP; Choueiri TK; Turchin A; McKay RR; Goyal L; Davis M; Kaymakcalan MD; Williams JS
    Cancer; 2015 Jan; 121(2):311-9. PubMed ID: 25236375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-VEGF Anticancer Drugs: Mind the Hypertension.
    Katsi V; Zerdes I; Manolakou S; Makris T; Nihoyannopoulos P; Tousoulis D; Kallikazaros I
    Recent Adv Cardiovasc Drug Discov; 2014; 9(2):63-72. PubMed ID: 26123049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypertension as a surrogate marker for the activity of anti-VEGF agents.
    Mir O; Ropert S; Alexandre J; Goldwasser F
    Ann Oncol; 2009 May; 20(5):967-70. PubMed ID: 19403940
    [No Abstract]   [Full Text] [Related]  

  • 14. m-Power Heart Project - a nurse care coordinator led, mHealth enabled intervention to improve the management of hypertension in India: study protocol for a cluster randomized trial.
    Srinivasapura Venkateshmurthy N; Ajay VS; Mohan S; Jindal D; Anand S; Kondal D; Tandon N; Rao MB; Prabhakaran D
    Trials; 2018 Aug; 19(1):429. PubMed ID: 30086778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Anticancer drugs under pressure].
    Ben Aïssa A; George AC; El M'Rabet FZ; Mach N; Dietrich PY; Pechère-Bertschi A
    Rev Med Suisse; 2011 Sep; 7(308):1761-6. PubMed ID: 21954818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of drugs affecting hypertension in bevacizumab-treated patients and examination of the impact on the therapeutic effect.
    Yagi K; Mitstui M; Zamami Y; Niimura T; Izawa-Ishizawa Y; Goda M; Chuma M; Fukunaga K; Shibata T; Ishida S; Sakurada T; Okada N; Hamano H; Horinouchi Y; Ikeda Y; Yanagawa H; Ishizawa K
    Cancer Med; 2021 Jan; 10(1):164-172. PubMed ID: 33231381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer Therapy-Related Hypertension: A Scientific Statement From the American Heart Association.
    Cohen JB; Brown NJ; Brown SA; Dent S; van Dorst DCH; Herrmann SM; Lang NN; Oudit GY; Touyz RM;
    Hypertension; 2023 Mar; 80(3):e46-e57. PubMed ID: 36621810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of cyclosporine induced hypertension: Results from a long-term observational study using different antihypertensive medications.
    Marienhagen K; Lehner F; Klempnauer J; Hecker H; Borlak J
    Vascul Pharmacol; 2019 Apr; 115():69-83. PubMed ID: 29933079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of vascular endothelial growth factor-a signaling induces hypertension: examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy.
    Curwen JO; Musgrove HL; Kendrew J; Richmond GH; Ogilvie DJ; Wedge SR
    Clin Cancer Res; 2008 May; 14(10):3124-31. PubMed ID: 18483380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Personalizing the Intensity of Blood Pressure Control: Modeling the Heterogeneity of Risks and Benefits From SPRINT (Systolic Blood Pressure Intervention Trial).
    Patel KK; Arnold SV; Chan PS; Tang Y; Pokharel Y; Jones PG; Spertus JA
    Circ Cardiovasc Qual Outcomes; 2017 Apr; 10(4):. PubMed ID: 28373269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.